Tag «PHASE 2 Treatment of Liver and Biliary Tract Disorders»

NIDUFEXOR

It’s only fair to share… NIDUFEXOR LMB763 4-[[benzyl-(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)amino]methyl]benzoic acid Nidufexor is a farnesoid X receptor (FXR) agonist. Molecular Weight 487.93 Formula C₂₇H₂₂ClN₃O₄ CAS No. 1773489-72-7 PHASE 2 Treatment of Liver and Biliary Tract Disorders, Agents for Diabetic Nephropathy, NOVARTIS Nidufexor 1773489-72-7, LMB-763, UNII-CJ1PL0TE6J, CJ1PL0TE6J, BCP28929, EX-A1854 Nidufexor pound LMB-763 pound(c) ZINC584641402 4-((N-benzyl-8-chloro-1-methyl-1,4-dihydrochromeno[4,3-c]pyrazole-3-carboxamido)methyl)benzoic acid HY-109096 CS-0039398   https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.9b01621 1 (7.6 g, 89% yield) as …